Form 8-K - Current report:
SEC Accession No. 0001171843-26-003154
Filing Date
2026-05-07
Accepted
2026-05-07 16:01:38
Documents
13
Period of Report
2026-05-07
Items
Item 2.02: Results of Operations and Financial Condition
Item 9.01: Financial Statements and Exhibits

Document Format Files

Seq Description Document Type Size
1 FORM 8-K f8k_050726.htm   iXBRL 8-K 15771
2 PRESS RELEASE exh_991.htm EX-99.1 52393
  Complete submission text file 0001171843-26-003154.txt   275353

Data Files

Seq Description Document Type Size
3 XBRL SCHEMA FILE gnw-20250101.xsd EX-101.SCH 3402
4 XBRL DEFINITION FILE gnw-20250101_def.xml EX-101.DEF 26066
5 XBRL LABEL FILE gnw-20250101_lab.xml EX-101.LAB 35956
6 XBRL PRESENTATION FILE gnw-20250101_pre.xml EX-101.PRE 24702
16 EXTRACTED XBRL INSTANCE DOCUMENT f8k_050726_htm.xml XML 2872
Mailing Address 901 GATEWAY BLVD, THIRD FLOOR SOUTH SAN FRANCISCO CA 94080
Business Address 901 GATEWAY BLVD, THIRD FLOOR SOUTH SAN FRANCISCO CA 94080 (650) 900-4520
Corvus Pharmaceuticals, Inc. (Filer) CIK: 0001626971 (see all company filings)

EIN.: 464670809 | State of Incorp.: DE | Fiscal Year End: 1231
Type: 8-K | Act: 34 | File No.: 001-37719 | Film No.: 26952942
SIC: 2834 Pharmaceutical Preparations
(CF Office: 03 Life Sciences)